Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Eloralintide
An investigational selective amylin-pathway agonist now in a broad Phase 3 programme.
Enicepatide
An investigational GLP-1/GIP dual agonist reported to be advancing towards Phase 3.
How far human research has progressed
Eloralintide
Phase 3 programme actively enrolling; published human data limitedEnicepatide
Phase 2 results reported by the sponsor; Phase 3 advancement statedHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Eloralintide
Enicepatide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Eloralintide
Enicepatide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Eloralintide
Enicepatide
Regulatory status (legal position, not proof it works)
Eloralintide
Not approved anywhere. The Phase 3 ENLIGHTEN programme is enrolling across obesity, type 2 diabetes, obstructive sleep apnoea, knee osteoarthritis and people already on incretin therapy.Enicepatide
Not approved anywhere. The sponsor reported positive Phase 2 results in 2026 and stated an intention to advance the compound towards Phase 3.Common claims
Eloralintide
- · Weight loss without incretin-style gastrointestinal burden
- · Useful added on top of existing incretin therapy
Enicepatide
- · Very large weight loss
- · Best-in-class dual agonist potency
How settled our evidence rating is
Eloralintide
Enicepatide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Eloralintide
No established human cancer signal for this compound.Enicepatide
No demonstrated human cancer signal. Class-level incretin precautions apply and remain under trial surveillance.What this adds up to, in plain English
Eloralintide
There is some early human signal, but it is far weaker than the broad claims made about it online.Enicepatide
There is some early human signal, but it is far weaker than the broad claims made about it online.A comparison is not a recommendation